(as of 3/17/2023)
AdHawk Microsystems delivers full-stack eye tracking technology - from custom silicon to cloud-based analytics - to unlock the connection between the eyes, the brain and the world around us. The company has developed wearable eye tracking products with unprecedented speed and data quality by replacing cameras and image processing with a highly customized microsystem that delivers game-changing computational and power efficiencies. The AdHawk solution is powering a new generation of “form-factor-first” smart glasses with all-day biometric sensing in Tier 1 OEM products. The technology is also being deployed in XR products, human-computer-interaction PC peripherals, and clinical instruments. Deep-tech breakthroughs at AdHawk have also positioned the company to develop the first fitness tracker for the brain: a consumer wearable device that will soon offer billions of people rich analytics on their cognitive processes, and actionable insights to improve their brain health and wellness.
AGED Diagnostics is using genomic innovation to develop the most accurate blood test for liver disease to help physicians keep patients in the monitoring program, reduce the financial burden for health insurers and improve patient outcomes through early detection and intervention.
American TelePhysicians (ATP) is a physicians-led and awards-winning virtual healthcare technology startup that is building the future of healthcare by establishing integrated online healthcare ecosystems to deliver affordable and accessible care to doorstep. ATP is a stakeholder at United Nations initiatives for sustainable development goals and has been selected by the US government for international trade missions. Using our network of specialist physicians and proprietary integrated one-stop virtual care technology solution (SmartClinix) that has built-in remote patient monitoring and data analytics systems, we partner with local and ancillary healthcare service providers to build online and onsite specialty care programs for all 3 clinical settings i.e., acute care, post-acute care and chronic care.
Coronary Artery Disease is our society’s biggest killer and requires risky and invasive open-heart surgery. This is why AMT medical has developed a ‘suture-less’ medical device that makes this procedure simpler for surgeons – and thus safer for patients. Our patented solution is already proven in a First in Human trial in 10 patients and makes bypass surgery ever less invasive.
aNUma is a digital therapeutics company using virtual reality (VR) to reduce the fear and distress suffered by people facing a terminal disease. The company’s multi-session program - for patients, caregivers, and loved ones - addresses the psychological, emotional, and spiritual needs of patients facing life-threatening disease, filling a critical and currently unmet need in palliative care. aNUma is raising $2M in seed capital to collect efficacy data, scale delivery, and move into a commercially supported study to demonstrate real-world health and economic benefits.
Aplife introduces the first digital probe discovery platform designed to develop a new generation of digital devices. Biosensor companies will be able to discover new receptors that can be applied to their devices. This is sustained by two main pillars: the in-situ fabrication of millions of receptor candidates in predefined locations and a proprietary semiconductor to massively test these candidates digitally.
AutoMedicus Corporation has developed a transformative medical device called the AutoPress that promises to decrease morbidity and mortality by automating the complex manual process of controlling patient blood pressure in critical situations such as during surgery and in the ICU. The AutoPress is the next revolution in closed loop medical device technology such as demonstrated with the artificial pancreas, automated anesthesia systems, and implantable defibrillators. There is currently no device on the market that will perform even a remotely similar function.
Brinter®, is a BioTech/MedTech company based in Santa Monica, CA, Winston-Salem, NC, and Turku Finland. We develop, license, and sell our in-house pre-clinical and clinical applications enabled by our patented and commercial 3D (bio)printing technology and (bio)materials. Our core applications are: Cartilaginous Bio-Implants, Wound Healing Bio-Bandages, Pre-clinical drug discovery & development solutions, and Clinical Complex Drug Printing Solutions. Our key partners and customers are clinics, research, and academia, hospitals, CROs, bio, and pharmaceutical companies.
CairnSurgical, Inc. is an early commercialization growth stage company that has developed a platform technology to improve surgical outcomes with image-derived, 3-D printed surgical guides. Our first product is a breast cancer surgery guide, commercial in EU and clinical stage in US. The Breast Cancer Locator™ System (BCL™) is a proprietary, patient-specific, surgical guidance system designed to achieve clear margins.
Our mission is to advance speech and language technology in the field of digital healthcare and wellness by replacing subjective measurements with objective, actionable measurements for patients, consumers, and clinicians
CisionVision is a developer of high contrast real-time imaging devices. The company focuses on the development of a medical device that uses imaging technology and visualizes chemical composition contrast between lymph nodes and fat.
Centese has developed Thoraguard, a digital system that provides AI-powered insights and automated drainage to help patients recover faster and with fewer complications following heart and lung surgery. The company has partnered with top hospitals nationwide to generate clinical evidence supporting Thoraguard's launch and is raising its Series B round to fund rapid commercialization.
Founded in 2016 (Boston, MA) by Harvard University alumni, Day Zero Diagnostics (DZD) is on a mission to transform the way infectious disease diagnostics are performed. By using novel sample preparation methods enabling nearly complete pathogen genomic recovery directly from clinical samples, whole-genome sequencing, and machine learning algorithms, DZD is creating a new class of sequencing-based in-vitro diagnostics. DZD aims to generate a stream of real-time sequencing data, rapidly and at scale, to change how we treat, track, manage, and combat infectious diseases and antibiotic resistance.
Delpor is a clinical stage biopharmaceutical company that develops once-yearly therapies for chronic conditions. The technology makes it possible for patients to achieve complete medication adherence for one full year without having to worry about taking their meds. Patients may go through a year without any symptoms, relapses, the stigma of taking medication, or the daily reminder that they are sick, almost like having a one-year cure in a disease area where there is no cure. The Company develops drug/device combination branded therapeutics. Delpor’s technology enables the sustained release of drugs through a small non-mechanical subcutaneous implant device lasting for 6-12 months. The device is placed under the skin during a 10-minute, simple, in-office, procedure using local anesthetic. After placement, it delivers therapeutic levels of a drug for as long as 1 year. Delpor is pursuing 6-12 month formulations of drugs targeting Mental Disorders, Addiction, Neuromuscular Diseases, and other CNS conditions. The Company’s pipeline includes 2 clinical assets: A 1-Year Risperidone for schizophrenia which is currently in Ph2 and is expected to advance to Ph3 within 12 months, and a 1-Year Naltrexone for Opioid Use Disorder which is about to complete Ph1. Delpor’s investors include Kairos Ventures, Cloudstone, The Zambon Group, and The family Office of Ernie Mario. The Company has also received ~$20 million dollars of support from the NIH.
Directed Systems is a medical software, data analytics and AI company headquartered with R&D in Cambridge UK and sales operations focused on the US. Their software is sold as a service to hospitals to help reduce the complications and costs associated with surgery and intensive care. Their breakthrough solution launched in mid 2022 optimizes care on a moment-to-moment basis through point of care FDA cleared software and cloud data analytics. The company's solution is 8x cheaper per patient and more effective than their nearest competitor and has been requested for procurement by three major US hospitals. They are raising $2.5 million to build sales traction in the US market and expand their engineering team to support sales and extend their solution to intensive care.
350,000 Coronary Artery Bypass Graft (CABG) procedures are performed in the U.S. annually (~900,000 worldwide), and the majority of those procedures (+75%) utilize harvested saphenous vein graphs (SVG). The vein grafts expand under the arterial pressure and are subject to reported degeneration and occlusion rates from 15-25% in the first year and as high as 50% at five years. DurVena is commercializing a photochemical tissue passivation therapy (“PTP”) that strengthens vein graft and improves long term patency. Extensive pre-clinical testing of PTP has been published in top peer-reviewed journals showing a significant increase in vein stiffness (5x) and a reduction in intimal hyperplasia (70% reduction), a precursor of stenosis and graft failure. The annual CABG market for PTP in just the US is $1B, and with secondary markets in peripheral artery disease and arteriovenous fistulas, the overall global market opportunity for the company is over $6.5B/yr.
EnlitenAI is building a SaaS based AI platform for personalizing the management of seizures using wearables/devices for continuous monitoring of neurological indicators. We are device agnostic and data hungry. Our platform offers immense potential for data monetization by multiple stakeholders such as Neurology centers, Pharmaceutical/Biomedical companies, Insurance Carriers and wearable/device OEMs.
ENTvantage Dx is a clinical stage diagnostic company that provides physicians with point-of-care information on the underlying cause of ear, nose and throat illnesses. Our first product market opportunity exceeds $1.4 billion the initial targeted markets annually. Use of the FDA Class II kit will improve the accuracy of their diagnosis, reduce the amount of antibiotics prescribed unnecessarily to treat sinusitis, and increase revenue to the clinic using established CPT reimbursement codes. Multicentered clinical trials are underway to gain FDA 510(k) De Novo clearance and CLIA Waiver.
Tzar Labs has made a significant breakthrough in early detection of cancer. The marker works on solid, haematological cancers and also soft tissue sarcomas. Tzar specialises in novel onco-biomarkers for screening and early-detection of cancer. Our highly successful results were published in the April 2021 Springer journal and Oxford’s Stem Cell in March 2023. They claim multiple global firsts: First All-Cancer Detection Blood Test; High accuracy at Early stage and First Prognostic Blood Test.
Eyedaptic, is a software technology company addressing the large unmet need in the ophthalmic field of AMD (Age Related Macular Degeneration). Our visually assistive solutions are based on open market Augmented Reality (AR) glasses and embeds our proprietary simulated natural vision software, which optimizes the person’s functional peripheral vision to help restore the entire scene for the wearer. Eyedaptic’s software is adaptive to the user’s particular vision limitation, as well as their environment and habits with machine learning and optimizes their field of view. The camera views the surroundings, manipulates the pixels and re-displays the image, with an adapted visual field for the wearer thereby effectively addressing central vision loss.
Harmonic Bionics is a commercial-stage robotics and digital health company disrupting the $14B physical medicine and rehabilitation markets through the digitization and automation of shoulder care. With a steady and growing demand for physical therapy in the US and throughout the world, Harmonic Bionics has developed Harmony SHR™: a bilateral upper extremity exoskeleton to aid in the rehabilitation process for those suffering with neurological and musculoskeletal movement impairments. In addition to the novel mechanical design of the system, the unprecedented data sets produced by Harmony’s high-speed and high-fidelity sensors have the potential to transform the industry by helping to create standardized and automated therapy protocols to drive a higher quality & quantity of interventions.
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
Invenio is combining its proprietary NIO Laser Imaging System with AI to provide real-time analysis of fresh tissue specimens in the OR. With the support of the Johnson & Johnson Lung Cancer Initiative and the NIH, we are initiating a study to develop and validate lung cancer detection algorithms to assist physicians in the evaluation of lung biopsies. We aim to enable surgeons to make accurate, well-informed decisions, leading to improved patient experience and outcomes, more efficient care, and increased hospital revenue. A next generation of our AI could provide real-time diagnosis, potentially including molecular prediction, which would enable immediate treatment.
Jointechlabs, Inc. is an emerging leader in point-of-care regenerative medicine therapies. Our portable, affordable devices and technology create the highest quality regenerative cells and enable simple-to-administer regenerative medicine therapies at the point-of-care. Major Markets (Total TAM $149B): Orthopedics & Sports Med, Aesthetics & Plastic Surgery & Wound healing.
Lazurite’s ArthroFree® System includes the wireless camera for arthroscopy and general endoscopy. For 50 years, the cables of conventional surgical cameras have been implicated in the inefficiencies and hazards of the OR. Fiber-optic cables are expensive to maintain, implicated in patient burns, and limit the dexterity of clinicians. With its wireless surgical camera, the ArthroFree System simplifies the sterile field, eliminates camera-cable-related burns and fires, and introduces freedom of movement to arthroscopy. It also projects cost-per-case savings up to 20%.
Leucadia Therapeutics is a preclinical medical device company that discovered an important mechanism, which clears toxins away and rejuvenates the lower front of the brain. That region is responsible for learning, memory, passion, pleasure, and fear. Small perturbations in this mechanism contribute to Alzheimer’s disease, frontotemporal dementia, and brain aging. The company has developed, and patented, a tiny implantable device that fixes what is essentially a plumbing problem. Currently, Leucadia Therapeutics is raising a Series A round to fund the first clinical trial of our device in 2023-24.
SafeBreak Vascular is the first FDA cleared break away device that separates when a damaging force is placed on the IV line and prevents the need for another needlestick for the patient, an IV restart for the nurse, and wasted medication and IV supplies for the hospital. A randomized clinical trial showed that SafeBreak had a 44% reduction in IV restarts compared to the standard of care, which would save a 200-bed hospital an estimated $100K annually when using SafeBreak. SafeBreak takes only 5 minutes to replace versus 20-30 minutes for the average IV restart. Nursing turnover in the US averaged 27% last year, and SafeBreak saves overworked nurses time. Patients win, nurses win, and hospitals win.
Lumendo is a Swiss-US dental startup. Our ambition is to disrupt the 1.6 MUSD endodontic device and consumables market with a novel and patent solution. To launch in the US, we are raising a 10 MUSD round by Q4 2023.
Luventix develops medical disease screening tests based on computational models that use urine gas chromatography data as input. Our platform lets us develop new tests in months rather than years, which has been the accepted healthcare norm. Unlike expensive genetic testing, which requires D/RNA samples, Luventix works with urine analytes. We can detect multiple diseases from a single sample, included but not limited to cancers. We are going to market with lab-developed tests and test panels that do not require FDA approval and will offer direct-to-consumer testing out of the gate. Long term we will pursue FDA approval of diagnostic versions of our tests and CPT/LCD code designation that will allow us to be in-network with payors nationwide. We have completed two prototype studies and models for prostate and bladder cancer with cohorts of 40 and 19 cancer patients, respectively.
Metfora is a spinout from the University of Arizona with a powerful new diagnostic technology. We analyze metabolites in blood to detect a broad range of chronic diseases. This addresses a $45B market opportunity. We have tested it on more than 650 patient samples and have filed two patents on the technology. The initial product will be a test for 4 lung diseases (COPD, ILD, pulmonary hypertension and asthma) that will be brought to market as a lab developed test (LDT). To date, we have raised $850K from multiple sources including STTR and SBIR grants from the NIH and the NSF. Our team includes two professors, an AI expert and a diagnostics industry veteran with complementary skill sets.
Neuralace Medical, Axon Therapy is the first non-invasive, magnetic field driven, transcutaneous neurostimulation device for peripheral neuropathic pain relief cleared by FDA (June 2021). Axon device MOA addresses Aβ nerve access while supporting CNS reconditioning, using a unique waveform and signal frequency needed to communicate most effectively with this nerve, leading to maximum clinical impact. Neuralace Medical’s mPNS (magnetic Peripheral Nerve Stimulation) targets the gap between prescription drug therapy and all other treatment options, including minimally invasive procedures. The Axon Therapy device is commercially available. Neuralace secured their first contract with the Veteran's Healthcare System at VA Augusta in December 2022 for 5 years and $1.4M.
Nocira was awarded "Emerging Neurology Device Company of the Year" (MedTech Outlook) and is in late stage clinical development of the 1st ever FDA-awarded "Breakthrough Device" for treating migraine – one of the largest and most urgent unmet needs in all medicine. >250 treatments in 5 studies showed Nocira's non-invasive device is by far more effective, faster acting, and more widely adoptable vs. any other current migraine device or drug – and as a drug-free, comfortable & pleasant, easy-to-use, consumer friendly home use product without any known significant side effects or contraindications. The patented Nocira system includes a mobile “App” that captures data about the patient’s specific migraine symptoms to control a disruptive new neuromodulation approach for a personalized treatment that is optimized for each migraine attack in each patient. Broad future pipeline opportunities include migraine prevention, expanding upon AI/machine learning and other Digital Health assets, and treating other major conditions (e.g., other headaches, seizure, stress/anxiety/depression, sleep disorders, opioid withdrawal).
We are using proprietary AI-based 3D scanning software on a smartphone to scan patients to assess their scoliosis, to address accuracy and radiation issues relative to the current system. We are then marrying that to our telehealth National Scoliosis Clinic to improve patient access, patient-centeredness, and experience. We've got great backing and strong momentum currently, nearing go-to-market, with solid primary research demonstrating our customer's needs.
Nutromics is an Australian-born, global diagnostics company on a mission to revolutionize diagnostics through our DNA-based sensor platform. This is a breakthrough technology combining multiple DNA-based sensors with minimally invasive microneedles that can track multiple crucial targets continuously and in real-time, giving clinicians critical, personalised insights. Our vision is a world with zero preventable deaths due to a lack of continuous diagnostic monitoring.
Omniscient Neurotechnology (o8t) is a pioneering brain mapping company that is revolutionizing brain care and brain potential through connectomics; big data applied to brain connectivity and function. Using innovations in medical imaging and machine learning, Omniscient is transforming the way we understand, diagnose and treat complex neurological and mental illnesses, leading to better outcomes for billions of people, and unlocking a revolution in brain potential. Omniscient's first product Quicktome is FDA cleared and has sparked the translation of connecomics into leading US neurosurgical centers, leading to better patient outcomes.
OnLume Surgical is an innovative imaging company with a patented platform for fluorescence-guided surgery (FGS). FGS is used in real-time during surgery to identify anatomy that is otherwise not visible to the human eye. FGS helps to improve surgical precision by optimizing the visibility of vasculature perfusion, cancer margins, nerves, lymphatic structures and other critical anatomy.
Paragate Medical is a clinical stage (FIH) startup, addresseing the #1 burden on healthcare system nowadays: the chronically fluid overloaded heart and kidney failure patients, who are considered the “frequent flyers” of the hospitals. The company develops the IPUD, a fully implantable device to actively and continuously prevent chronic fluid accumulation, and hence, the resultant need for frequent and expensive hospital readmissions. Paragate solution is the first of its kind to provide a truly 24/7 home-based active treatment, that goes well beyond the monitoring.
Integrative solutions for migraine and anxiety markets using digital device and visual pathway based patented Narrow Band Green Light (nbGL) pioneered by world renowned Harvard migraine and neurology specialist Dr. Rami Burstein who is a Percept advisor.
Qlife strives to revolutionize the market for clinical at-home biomarker testing. The company has built Egoo Health - a highly versatile In-Vitro Diagnostics self-testing platform, which facilitates tests for a broad range of clinical-grade biomarkers. The platform is easy to use, low cost, and suitable for use in people’s homes or decentral testing locations. Egoo Health is the world's first self-test at-home platform for immuno-diagnostics biomarkers, which will empower people with more accessible ways to understand their clinical health. Egoo Health is intended for quick access to clinical biomarker data in primary healthcare, community and home settings - democratizing access to clinical-grade biomarker data.
Bloodborne infections which, include Sepsis, are a significant worldwide health concern that is worsening over time as the number of cases grow worldwide and antibiotic resistance becomes more prevalent. Radiatric has developed a highly effective method, using our patented technology, to treat bloodborne infections including sepsis. The RAD-01 extra-corporeal medical device uses a safe and unique non-pharmacological process for targeting and killing bacteria in the bloodstream, even when antibiotics are not effective. The device is intended to be used in early stages and could be used in conjunction with antibiotics. Radiatric has successfully developed and tested the Prototype RAD-01 device.
Resilient Lifescience is a Pittsburgh-based startup building a wearable medical device to prevent opioid overdose deaths using naloxone, even when no one else is around.
SAGE has developed a highly effective approach to identify the best treatment for cancer patients that overcomes the inherent limitations of genomic testing. This is accomplished by creating 3D microtumor replicates from a fresh tissue biopsy that reflect the patient tumor's heterogeneity and extracellular matrix.
Texas-based Seno Medical’s Imagio® OA/US Breast Imaging System combines laser optics and grayscale ultrasound to provide fused functional, morphological, and anatomical imaging. The PMA approved Imagio® Breast Imaging System assists physicians in differentiating between benign and malignant breast lesions using a novel combination of ultrasound and opto-acoustic (OA/US) technology. The opto-acoustic images provide a unique blood map in and around breast masses, while the ultrasound provides a traditional anatomical image. Through the appearance or absence of two hallmark indicators of cancer — angiogenesis and hypoxia — Seno Medical has shown that the Imagio® OA/US Breast Imaging System will be a more effective tool to help radiologists confirm or rule out malignancy compared with traditional diagnostic imaging modalities. And it does this without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents. In addition to the novel imaging provided by the Imagio® System, Seno includes an artificial intelligence (AI) decision-support tool (SenoGram®) to help physicians interpret the new images. This AI tool, along with training and certification, helps radiologists transition from ultrasound alone to OA/US imaging to assign the likelihood of malignancy more precisely.
Symbios is a Swiss medical technology company, and the leader in custom-made orthopaedic implants for hip and knee joint replacement. For 30 years, Symbios has been the pioneer and leader in custom-made orthopaedic implants and individualized solutions. Designing and manufacturing custom-made implants and solutions to adapt perfectly to each patient’s individual anatomy and restore the quality of life of each patient.
Theradaptive is an MIT spin-out that has developed a precision therapeutic delivery platform with a total addressable market of nearly $300B in several clinical indications. Using its proprietary platform Theradaptive can convert any recombinant protein into a variant that can be painted onto implantable materials. This makes it possible to coat implants, devices, and injectable carriers to deliver a therapeutic directly to where it is needed most while avoiding systemic exposures that can lead to adverse events.
ThinkSono built the world's first software for detection of deep vein thrombosis (DVT). DVT is a blood clot and is the number one cause of preventable hospital death worldwide. The software is economically and clinically validated, and is piloted in over 11 hospitals across Europe, involving 600 patients and 50 healthcare staff. The company is now seeking regulatory approval prior to full commercial use in the US and EU.
Thrive Bioscience’s instruments and software provide automated imaging and analytics of live cells and tissues for research and drug discovery. Thrive instruments automatically build extensive databases of terabytes of time-series images at 100 focal planes of all the cells in all the wells in cell culture plates.
TibaRay is an early stage company developing a new Radiation Therapy system that will treat cancer patients in a fraction of a second, resulting in dramatically reduced collateral damage to normal tissue leading to better outcomes. The well-patented enabling technological breakthroughs came out of the SLAC National Accelerator Lab and Stanford University Healthcare and uniquely position TibaRay to disrupt this $7B market by curing cancer in a FLASH.
TYBR Health is transforming post-operative recovery for patients with a natural hydrogel that keeps internal organs scar-free after surgery.
Using AI and Machine learning, we created the first 3D ultrasound of the spine for clinicians. With this technology, clinitians can view the spine in three dimensions without any harmful radiation allowing for improved diagnosis and treatment of back issues. The technology is precise enough to allow for internventions to be performed with accruacy similar to CT and X-ray. Through its groundbreaking combination of AI and Ultrasound technologies, Verdure is not just displacing current uses of established medical imaging devices, but also has the potential to lead to new standards of care.
THE VESTECK “SUTURE-TIGHT” CATHETER DELIVERS NITINOL SUTURES, SECURING ENDOVASCULAR AORTIC REPAIR GRAFTS TO THE AORTA AT THE TIME OF INITIAL IMPLANT OR DURING REPAIR PROCEDURES.
Ziteo Medical is focused on the development of a portable/handheld imaging system for surgical guidance. The instrument will help surgeons in observing tumors while doing surgery by providing 3-D images of cancerous tissue inside patient's body. Its first product "New Vew 3-D 100" is the smallest 3-D visualization system and has the sensitivity to distinguish between close sentinel lymph node (SLN). The system will include the principles of various imaging modalities, including radiotracer, ultrasound, visual and fluorescence imaging. The company was selected by the California Life Science Institute (CLSI)- FAST Advisory Program in December 2015 to learn the different aspects including business models, product development, and commercialization strategy.